Clinical Outcome Analysis in “High-Risk” Versus “Low-Risk” Patients Eligible For National Surgical Adjuvant Breast and Bowel B-39/Radiation Therapy Oncology Group 0413 Trial: Five-Year Results

Patel, Rakesh; Christensen, Merrill J.; Hodge, Charles; Adkison, Jarrod B.; Das, Rupak K.

doi:10.1016/j.ijrobp.2007.12.005

Cited by 53 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result, the outcomes of these studies have been much improved (Table 6). 12,[16][17][18][19][20][21][67][68][69][70][71][72][73][74][75][76][77][78][79] Ochsner Clinic experience…”

Section: London (Ontario) Regional Cancer Center's Pilot Studymentioning

confidence: 99%

“…73 Between 2000 and 2005, 273 patients were treated with a total dose of 32-34 Gy in eight to ten twicedaily fractions within 4-5 days, using HDR BT. The majority of patients (n = 247) were treated using multicatheter BT, while the others (n = 26) were treated with a MammoSite (Cytyc Corporation, Marlborough, MA, USA) applicator.…”

Section: University Of Wisconsin Experiencementioning

confidence: 99%

“…In December 2006, the trial closed enrollment to low-risk patients, thereby limiting further accrual to patients satisfying one or more of the high-risk criteria, including age less than 50 years, estrogen receptor negativity, or one to three positive nodes. 73 However, the principal investigators of the study suggested avoiding the overextension of APBI (in daily clinical practice outside clinical trials) beyond the conservative patient The role of CT image-based conformal treatment planning of breast implants A good implant in interstitial BT is characterized by an adequate dose coverage of the PTV, a high dose homogeneity inside, and a steep dose fall-off outside the target volume.…”

Section: American (Nsabp B-39/rtog 0413) Multicentric Randomized Apbimentioning

confidence: 99%

See 2 more Smart Citations

Current status and perspectives of brachytherapy for breast cancer

Polgár

Major

2009

Int J Clin Oncol

View full text Add to dashboard Cite

Before the era of breast-conserving therapy, brachytherapy implants were used to treat large inoperable breast tumors. In later years, interstitial brachytherapy with rigid needles or multiple flexible catheters has been used to deliver an additional (boost) dose to the tumor bed after breast-conserving surgery and whole-breast irradiation. Reexcision followed by reirradiation using interstitial breast implants has also been implemented as an alternative to mastectomy to treat ipsilateral breast local recurrence after previous breast-conserving therapy. In the past two decades, the new concept of accelerated partial breast irradiation opened a new perspective for breast brachytherapy. The first technique utilized in early accelerated partial breast irradiation studies was multicatheter interstitial brachytherapy. Beyond classical interstitial brachytherapy, recently, new intracavitary applicators have been developed in the United States to decrease the existing barriers against the widespread use of multicatheter brachytherapy. Furthermore, interstitial low-dose-rate seed implants have also been implemented as an alternative for stepping-source multicatheter brachytherapy. In this article, we give an overview of the past achievements, current status, and future perspectives of breast brachytherapy.

show abstract

“…As a result, the outcomes of these studies have been much improved (Table 6). 12,[16][17][18][19][20][21][67][68][69][70][71][72][73][74][75][76][77][78][79] Ochsner Clinic experience…”

Section: London (Ontario) Regional Cancer Center's Pilot Studymentioning

confidence: 99%

Section: University Of Wisconsin Experiencementioning

confidence: 99%

Section: American (Nsabp B-39/rtog 0413) Multicentric Randomized Apbimentioning

confidence: 99%

See 1 more Smart Citation

Current status and perspectives of brachytherapy for breast cancer

Polgár

Major

2009

Int J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Another significant APBI study (247/273 multicatheter brachytherapy; 26 MammoSite™) with 5 year results (median 49 months follow-up) used the NSABP/RTOG intergroup criteria to define "high and low risk groups" by having one or more of the following features: age < 50 years, estrogen receptor negative, or one to three positive nodes without extra-capsular spread [19]. Impor-…”

Section: Multiple Catheter Tube and Buttonmentioning

confidence: 99%

Assessment of Accelerated Partial Breast Irradiation as Monotherapy Following Breast Conserving Surgery in the Treatment of Favorable Risk Breast Cancer

Sharma¹,

Ansari²,

Churchill³

et al. 2018

ABCR

View full text Add to dashboard Cite

show abstract

“…Leczenie promieniami przeprowadza się po wygojeniu loży po operacji i uzyskaniu wyniku badania histopatologicznego. Odsetek wznów miejscowych po czasie obserwacji 5-11 lat wynosi od 0% do 15%, w większości badań jest to odsetek 2,9-4,7% [6][7][8][9][10][11][12][13][14][15].…”

Section: Wyniki Badań Nad Apbi Bez Randomizacjiunclassified

Czy napromienianie części piersi powinno się stać standardowym elementem oszczędzającego leczenia chorych na wczesnego raka piersi? Głos na nie

Niwińska¹

2014

Nowotwory. Journal of Oncology

View full text Add to dashboard Cite

show abstract

Clinical Outcome Analysis in “High-Risk” Versus “Low-Risk” Patients Eligible For National Surgical Adjuvant Breast and Bowel B-39/Radiation Therapy Oncology Group 0413 Trial: Five-Year Results

Cited by 53 publications

References 11 publications

Current status and perspectives of brachytherapy for breast cancer

Current status and perspectives of brachytherapy for breast cancer

Assessment of Accelerated Partial Breast Irradiation as Monotherapy Following Breast Conserving Surgery in the Treatment of Favorable Risk Breast Cancer

Czy napromienianie części piersi powinno się stać standardowym elementem oszczędzającego leczenia chorych na wczesnego raka piersi? Głos na nie

Contact Info

Product

Resources

About